绝经期激素治疗与卒中风险:全国队列研究
该研究基于丹麦5个登记库构建1995—2010年51至70岁女性全国历史队列,纳入980 003名女性,其中20 199例发生卒中。结果显示当前使用口服激素治疗与卒中风险升高相关,经皮给药未增加风险,阴道雌激素与风险降低相关。
要点
- 口服联合或单用雌激素激素治疗与缺血性卒中风险升高相关
- 经皮激素治疗未显示与卒中风险相关
- 阴道雌激素与卒中风险降低相关
核心结论
- 口服激素治疗增加卒中风险,主要归因于缺血性卒中,与随机研究结论一致。
- 经皮激素治疗未增加卒中风险,阴道雌激素与卒中风险降低相关。
研究设计与样本
- 全国历史队列研究,链接丹麦5个登记库,纳入1995—2010年51至70岁女性980 003名。
- 暴露数据来自国家药品统计登记库,卒中诊断来自国家患者或死因登记库。
- 采用Poisson回归模型拟合含时变协变量的多因素校正率比。
主要发现
- 共20 199名女性发生卒中,其中78%为缺血性、12%为出血性、10%为蛛网膜下腔出血。
- 36%女性曾使用激素治疗;当前使用者的相对率为1.16(95%CI 1.12-1.22)。
- 与从未使用者相比,持续联合雌激素/孕激素口服治疗的全卒中率比为1.29(95%CI 1.21-1.37)。
- 周期性联合口服治疗的全卒中率比为1.11(95%CI 1.04-1.20),单用雌激素口服治疗为1.18(95%CI 1.10-1.26)。
- 风险升高源于缺血性卒中而非出血性卒中;经皮给药与卒中风险无关,阴道雌激素与风险降低相关。
临床怎么用
- 处方绝经期激素治疗时应评估卒中风险,尤其口服制剂。
- 对卒中风险较高的女性,可考虑经皮或阴道给药途径。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Double-blind randomized studies on the effects of oral postmenopausal hormone therapies were stopped mainly because of increased risk of stroke. We aimed to assess the risk of all strokes and various subtypes associated with hormone therapy and explore the influence of regimens and routes of administration. METHODS: A national historical cohort of women aged 51 to 70 years from 1995 to 2010 was established by linking 5 Danish registries. The National Registry of Medicinal Product Statistics provided information on hormone therapy exposure and the National Patient or Cause of Death Registries supplied data regarding stroke diagnoses (ischemic/hemorrhagic/subarachnoid hemorrhage). Multiply adjusted rate ratios with time-varying covariates were fitted in Poisson regression models. RESULTS: Of the 980 003 included women, 20 199 suffered a stroke (78% ischemic, 12% hemorrhagic, and 10% subarachnoid hemorrhage). In total, 36% of women used hormone therapy. Current use conferred a relative rate of 1.16 (95% confidence interval, 1.12-1.22). Compared with never users, the increased rate ratio of all stroke with continuous, cyclic combined estrogen/progestin, and estrogen only oral therapies were 1.29 (95% confidence interval, 1.21-1.37), 1.11 (95% confidence interval, 1.04-1.20), and 1.18 (95% confidence interval, 1.10-1.26), respectively. The increased risk was because of ischemic stroke, but not hemorrhagic stroke. Transdermal application of hormone therapy was not associated with risk of stroke. Vaginal estrogen was associated with a decreased risk of stroke. CONCLUSIONS: In a national setting, we found an increased risk of stroke, based on ischemic stroke, with oral hormone therapies that was comparable to findings from randomized studies. We found no risk of stroke with transdermal application and a reduced risk with vaginal estrogen.
引用
- Løkkegaard E, Nielsen LH, Keiding N, et al. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study. Stroke. 2017. PMID: 28626058. doi:10.1161/STROKEAHA.117.017132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。